Vaccine-maker stocks including Pfizer have been seeing a dip after the nomination of RFK Jr., a known vaccine skeptic, to lead HHS under Trump's presidency.
Pfizer's stock fell to a 52-week low of $25.14. This could be attributed to the unpredictability and uncertainty this nomination brings to the pharmaceutical industry. However, amidst this downward trend, Pfizer has been described as a
top-ranked value stock with possible upside thanks to its Covid products. However, investors are cautious due to the company's soft earnings, despite a Q3 earnings beat. There is speculation whether the company can rise amidst the market challenges, with targets as high as $60. Amidst these fluctuations, there have been reports of insider buying, suggesting confidence in the stock. Pfizer is also exploring the sale of its hospital drugs unit and is facing an activist battle with Starboard taking a $1 billion stake. This makes Pfizer an interesting investment with low volatility despite the market dips, providing opportunities for high growth and passive income.
Pfizer Stocks News Analytics from Tue, 07 May 2024 07:00:00 GMT to Sat, 16 Nov 2024 20:21:59 GMT -
Rating -4
- Innovation 4
- Information 5
- Rumor -3
